EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of miR ‐150‐5p in Human Amniotic Membrane Mesenchymal Cell‐Derived Extracellular Vesicles as a Novel Mechanism Driving Cardioprotection

Nunzio Alcharani, Laura Tesoro, Javier Díez-Mata, José Luis Zamorano, Marta Saura, Maite Iglesias, Carlos Zaragoza

European Journal of Clinical Investigation · 2026-05 · 56 (5)

DOI: 10.1111/eci.70212 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 28.04.2026. Verfasst von Nunzio Alcharani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Unidad Mixta de Investigación Cardiovascular Universidad Francisco de Vitoria, Hospital Ramon y Cajal (IRYCIS), Madrid, Spain. Hauptthemen laut MEDLINE: MicroRNAs, Extracellular Vesicles, Mesenchymal Stem Cells, Myocardial Reperfusion Injury. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad Francisco de Vitoria.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Human amniotic membrane mesenchymal stem cells (hAMSCs) hold strong cardioprotective potential, yet their mechanisms of action remain largely elusive. Methods and Results C57BL/6 mice were subjected to cardiac ischemia/reperfusion (I/R) and received intravenous (IV) 2 × 10 5 hAMSCs at 2, 7 or 14 days post‐reperfusion. Cardiac function and MIAT/miR‐150/HOXA4 signalling were assessed. Mice treated 2 days post‐I/R markedly improved LVEF and reduced myocardial necrosis and fibrosis by Day 21. Minimal hAMSC engraftment, evidenced by SSEA‐4 immunostaining, suggests paracrine rather than direct cellular effects. Guided by GWAS implicating miRNAs in myocardial infarction, we identified miR‐150 as a key effector, finding that hAMSC upregulated cardiac miR‐150 and suppressed HOXA4, a profibrotic target in ischemic myocardium. In parallel, hAMSC treatment reduced cardiac MIAT, a lncRNA that sequesters miR‐150, uncovering a mechanism of cardioprotection via MIAT downregulation post‐reperfusion. Notably, CRISPR‐Cas9 miR‐150‐silenced hAMSC exhibited severely impaired cardioprotective effects compared to wild‐type cells, confirming the functional role of miR‐150. miR‐150 was identified as a key extracellular vesicle (EV) cargo released by hAMSC under hypoxic conditions, both in vitro and in hAMSC‐injected I/R mice. Strickingly, administration of miR‐150‐enriched EVs to mice recapitulated the therapeutic benefits of hAMSC, underscoring miR‐150‐5p as central mediator of hAMSC‐iduced cardioprotection. Conclusions hAMSCs promote cardioprotection following I/R via the MIAT/miR‐150‐5p/HOXA4 axis, in which miR‐150‐5p plays a central role. These findings provide loss‐of‐function evidence about the therapeutic potential of hAMSC‐derived EVs as a novel cell‐free exosome‐based strategy for the treatment of acute myocardial infarction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsExtracellular VesiclesMesenchymal Stem CellsMyocardial Reperfusion InjuryAmnionMesenchymal Stem Cell TransplantationMyocardial InfarctionAnimalsHumansMice, Inbred C57BLMiceHomeodomain ProteinsMaleMyocardium

Stichwörter der Autor:innen

HOXA4MIATacute myocardial infarctioncardioprotectionextracellular vesicleshuman amniotic mesenchymal stem cellsischemia/reperfusionmiR‐150‐5p

Substanzen

MicroRNAsMIR150, humanHomeodomain ProteinsMirn150 microRNA, mouse

Autor:innen und Institutionen

  • Unidad Mixta de Investigación Cardiovascular Universidad Francisco de Vitoria, Hospital Ramon y Cajal (IRYCIS), Madrid, Spain.
  • Departamento de Cardiología, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
  • Unidad de Fisiología, Departamento de Biologia de Sistemas, Universidad de Alcalá (IRYCIS), Alcala de Henares, Madrid, Spain.
  • Facultad de Ciencias Experimentales, Universidad Francisco de Vitoria, Madrid, Spain.

Förderung

  • Universidad Francisco de Vitoria

Zitieren

APA

Alcharani, N., Tesoro, L., Díez-Mata, J., Zamorano, J. L., Saura, M., Iglesias, M., & Zaragoza, C. (2026). Identification of miR ‐150‐5p in Human Amniotic Membrane Mesenchymal Cell‐Derived Extracellular Vesicles as a Novel Mechanism Driving Cardioprotection. European Journal of Clinical Investigation, 56(5). https://doi.org/10.1111/eci.70212

Vancouver

Alcharani N, Tesoro L, Díez-Mata J, Zamorano JL, Saura M, Iglesias M, et al. Identification of miR ‐150‐5p in Human Amniotic Membrane Mesenchymal Cell‐Derived Extracellular Vesicles as a Novel Mechanism Driving Cardioprotection. European Journal of Clinical Investigation. 2026;56(5). doi:10.1111/eci.70212

BibTeX
@article{Alcharani2026,
  author = {Alcharani, Nunzio and Tesoro, Laura and Díez-Mata, Javier and Zamorano, José Luis and Saura, Marta and Iglesias, Maite and Zaragoza, Carlos},
  title = {Identification of miR ‐150‐5p in Human Amniotic Membrane Mesenchymal Cell‐Derived Extracellular Vesicles as a Novel Mechanism Driving Cardioprotection},
  journal = {European Journal of Clinical Investigation},
  year = {2026},
  volume = {56},
  number = {5},
  doi = {10.1111/eci.70212}
}
Kostenlos starten →